Federal regulators sent dozens of letters to companies in September warning them that their advertisements for drugs are misleading and could lead to repercussions unless fixed.
The Food and Drug Administration on Sept. 16 released 65 letters it sent on Sept. 9 to companies, including Eli Lilly and Novo Nordisk. President Donald Trump signed a memorandum that day directing officials to enforce existing rules surrounding direct-to-consumer advertising for drugs.
In letters to Eli Lilly, FDA officials said that advertisements for weight loss products, including one that originally appeared in a special held by Oprah Winfrey, did not present people with accurate information about possible side effects….